News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Related Content
Trending on PharmExec
1
The Agentic AI Revolution in Biopharma
2
How Cortisol-Targeted Approaches Might be Paired with GLP-1 Medications
3
Novartis Investors Share Concerns Over M&A Strategy: Report
4
Artisan Partners’ Director Calls for Novartis Board Shake-Up
5